Mereo BioPharma (MREO) Accumulated Depreciation (2022 - 2026)

Mereo BioPharma (MREO) has reported Accumulated Depreciation for 5 consecutive years, with $978000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Depreciation fell 3.74% year-over-year to $978000.0; the TTM figure through Mar 2026 stood at $978000.0 (down 3.74% YoY), while the FY2025 annual figure was $1.1 million, up 14.33% from the prior year.
• Accumulated Depreciation declined to $978000.0 in Q1 2026 per MREO's latest filing, from $1.1 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $1.1 million in Q2 2025 and bottomed at $736000.0 in Q4 2022.
• Historically, Accumulated Depreciation has averaged $945272.7 across 5 years, with a median of $964000.0 in 2024.
• Annual changes were most pronounced in 2025 — Accumulated Depreciation grew 26.57% — and 2026, when it declined 3.74%.
• Mereo BioPharma's Accumulated Depreciation stood at $736000.0 in 2022, then grew by 8.7% to $800000.0 in 2023, then grew by 18.62% to $949000.0 in 2024, then advanced by 14.33% to $1.1 million in 2025, then declined by 9.86% to $978000.0 in 2026.
• Business Quant data shows MREO's Accumulated Depreciation at $978000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.0 million in Q3 2025.